Evidence-based efficacy and clinical applications of esketamine nasal spray for major depressive disorder with suicidal ideation or behavior
10.3760/cma.j.cn113661-20250322-00141
- VernacularTitle:艾司氯胺酮鼻喷雾剂治疗伴自杀意念或行为抑郁症患者的循证依据与临床应用
- Author:
Xuemei LIAO
1
;
Yang LI
;
Qin XIN
;
Miaomiao JIA
;
Tianmei SI
Author Information
1. 北京大学第六医院 北京大学精神卫生研究所 国家卫生健康委员会精神卫生学重点实验室（北京大学）国家精神心理疾病临床医学研究中心（北京大学第六医院），北京 100191
- Publication Type:Journal Article
- Keywords:
Depressive disorder;
Suicide;
Antidepressive Agents;
Esketamine;
Nasal spray
- From:
Chinese Journal of Psychiatry
2025;58(10):728-735
- CountryChina
- Language:Chinese
-
Abstract:
Major depressive disorder is a prevalent and debilitating mental disorder worldwide. Suicidal ideation and behavior represent a severe clinical manifestation closely associated with high mortality and disease burden. Current antidepressants have a delayed onset of action and fail to address the urgent need for rapid symptom relief in patients with major depressive disorder with suicidal ideation or behavior (MDSI). The glutamatergic antidepressant esketamine has demonstrated rapid antidepressant efficacy and a tolerable safety profile in patients with MDSI in multiple clinical trials, making it a promising therapeutic option. Esketamine is a non-selective, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In 2023, the nasal spray formulation was approved in China for use in combination with oral antidepressants to alleviate depressive symptoms in adults with MDSI. This review summarizes the latest clinical research progress on esketamine nasal spray for MDSI, providing evidence-based guidance for psychiatrists in clinical decision-making.
